Friedrich Bootz

Friedrich Bootz

Auto-generated profile, based on publicly available information

Friedrich Bootz

Department of Otorhinolaryngology, Head & Neck Surgery, University Hospital Bonn, 53127Bonn, Germany

Research Focus & Metrics

Academic Career Length

35Years (1992-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 April 2020 in Epigenetics
Verified
Journal Article
Closed access
LVLuka de Vos
Luka de Vos
IGIngela Grünwald
Ingela Grünwald
EBEmma Grace Bawden
Emma Grace Bawden
JDJörn Dietrich
Jörn Dietrich
KSKathrin Scheckenbach
Kathrin Scheckenbach
DDDimo Dietrich
Dimo Dietrich
CTLA-4 blocking therapeutic antibodies are currently under investigation in head and neck squamous cell carcinoma (HNSCC). A better understanding of the epigenetic regulation of the CD28 superfamily members CD28, CTLA-4, and ICOS and their B7 ligands, CD80 and CD86, could support the development of biomarkers for response prediction to anti-CTLA-4 immunotherapy.We investigated methylation of the encoding genes CD28, CTLA4, ICOS, CD80, and CD86 at single CpG resolution (51 CpG sites) in a cohort of HNSCC (N = 528) and normal adjacent tissue samples (N = 50) provided by The Cancer Genome Research Atlas, in isolated blood leukocytes from healthy individuals (N = 28), and HNSCC cell lines (N = 39). We analysed methylation levels with regard to mRNA expression, overall survival, mutational load, interferon-γ signature, and signatures of immune cell infiltrates.Depending on the location of the CpG sites (promoter, promoter flank, gene body, and intergenic sites), we found significant differences in methylation levels among isolated leukocytes, between leukocytes and HNSCC cell lines, and among HNSCCs. Methylation of all analysed genes correlated inversely or positively with mRNA expression, depending on the CpG site. CD28, CTLA4, and ICOS revealed almost identical correlation patterns. Furthermore, we found significant correlations with survival and features of response to immunotherapy, i.e. interferon-γ signature, signatures of tumour infiltrating immune cells, and mutational load.Our results suggest CD28, CTLA4, ICOS, CD80, and CD86 expression levels are epigenetically co-regulated by DNA methylation. This study provides rationale to test their DNA methylation as potential biomarker for prediction of response to CTLA-4 immune checkpoint inhibitors.

20 July 2020 in Immunotherapy
Verified
Journal Article
Closed access
LVLuka de Vos
Luka de Vos
JDJörn Dietrich
Jörn Dietrich
SSSebastian Strieth
Sebastian Strieth
FBFriedrich Bootz
Friedrich Bootz
DDDimo Dietrich
Dimo Dietrich
AFAlina Franzen
Alina Franzen
Aim: We investigated DNA methylation patterns of immune checkpoint genes PD-1, PD-L1, PD-L2, CTLA4 and an adjacent long noncoding RNA in papillary thyroid carcinoma (PTC). Materials & methods: DNA ...

1 May 2010
Verified
Conference Paper
Closed access
MRMarkus Rilk
Markus Rilk
DKDaniel Kubus
Daniel Kubus
FWFriedrich M. Wahl
Friedrich M. Wahl
KEKlaus W. G. Eichhorn
Klaus W. G. Eichhorn
IWIngo Wagner
Ingo Wagner
FBFriedrich Bootz
Friedrich Bootz
In this video we show our current prototype for robot assisted endoscopy. The system requires only few and simple instructions from the surgeon, in order to guide the endoscope in an intelligent, autonomous, and safe way: The surgeon tells what to do and the robot decides how to carry out the task by choosing the best manipulation primitive in every control cycle. Several sensors are integrated into the decision process: The endoscope camera, a stereo camera system, a force/torque sensor, a biomechanical model based on CT data and statistical knowledge, a position and velocity sensor for the manipulator, and interface devices like a foot switch. The executed manipulation primitive is handled by a hybrid controller allowing to switch the control mode (e.g. trajectory following or force control) for each degree of freedom of the task frame individually.

22 December 2020 in Epigenomics
Verified
Journal Article
Closed access
CBChristopher Bockhorst
Christopher Bockhorst
JDJörn Dietrich
Jörn Dietrich
TVTimo J Vogt
Timo J Vogt
RSRoland H Stauber
Roland H Stauber
SSSebastian Strieth
Sebastian Strieth
LVLuka de Vos
Luka de Vos

30 October 2019 in BMC Cancer
Verified
Journal Article
Open access
PDF file
MBMarie K. Budde
Marie K. Budde
WKWalther Kuhn
Walther Kuhn
MKMignon-Denise Keyver-Paik
Mignon-Denise Keyver-Paik
FBFriedrich Bootz
Friedrich Bootz
JKJörg Christoph Kalff
Jörg Christoph Kalff
ISIngo Schmidt-Wolf
Ingo Schmidt-Wolf
Background: Research shows disparities in cancer outcomes by ethnicity or socio-economic status. Therefore, it is the aim of our study to perform a matched-pair analysis which compares the outcome of German and non-German (in the following described as ‘foreign’) cancer patients being treated at the Center for Integrated Oncology (CIO) Köln Bonn at the University Hospital of Bonn between January 2010 and June 2016. Methods: During this time, 6314 well-documented patients received a diagnosis of cancer. Out of these patients, 219 patients with foreign nationality could be matched to German patients based on diagnostic and demographic criteria and were included in the study. All of these 438 patients were well characterized concerning survival data (Overall survival, Progression-free survival and Time to progression) and response to treatment. Results: No significant differences regarding the patients’ survival and response rates were seen when all German and foreign patients were compared. A subgroup analysis of German and foreign patients with head and neck cancer revealed a significantly longer progression-free survival for the German patients. Differences in response to treatment could not be found in this subgroup analysis. Conclusions: In summary, no major differences in survival and response rates of German and foreign cancer patients were revealed in this study. Nevertheless, the differences in progression-free survival, which could be found in the subgroup analysis of patients with head and neck cancer, should lead to further research, especially evaluating the role of infectious diseases like human papillomavirus (HPV) and Epstein-Barr virus (EBV) on carcinogenesis and disease progression.

14 November 2012 in Head & Neck
Verified
Journal Article
Open access
PDF file
MJMark Jakob
Mark Jakob
HHHatim Hemeda
Hatim Hemeda
KBKirsten Bruderek
Kirsten Bruderek
AGAndreas O. H. Gerstner
Andreas O. H. Gerstner
FBFriedrich Bootz
Friedrich Bootz
Sven BrandauSven Brandau
Sven Brandau
Background Mesenchymal stem cells (MSCs) are multipotent mesenchymal progenitor cells, originally identified in bone‐marrow. Little is known about MSCs of the head and neck region. We investigated cell biological properties with a potential impact on wound healing of 2 different tissue‐resident MSC populations. Methods MSCs were isolated from human nasal mucosa (nmMSCs) and parotid gland (pgMSCs). Clonogenic potential, cell surface markers, cytokine secretion, chemokine receptor expression, mobility, and adhesion to extracellular matrix were examined in unstimulated and stimulated MSCs. Results NmMSCs had the higher clonogenic potential. PgMSCs showed a broader panel of chemokine receptor expression and displayed higher mobility, especially after challenge with bacterial lipopolysaccharide (LPS). NmMSCs were less mobile and showed increased LPS‐induced secretion of the inflammatory cytokine interleukin‐8 (IL‐8) compared with pgMSCs. Conclusion These data highlight functional differences between tissue‐resident MSCs of the head and neck region, which may impact functional properties of these cells in response to trauma or infection. © 2012 Wiley Periodicals, Inc. Head Neck, 35: 1621–1629, 2013